Results from the Phase 3 VISIONARY trial showed a 97.1% reduction in the risk of a composite kidney outcome event of kidney ...
With more than 20 years of experience in the pharmaceutical industry, Brian is a strategic leader focused on advancing access to innovative therapies and helping teams navigate complex challenges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results